Federal cannabis status is now two-track. (1) FDA-approved cannabis drug products and state-medical-licensed entities moved to Schedule III by Attorney General Order, with the final rule effective 2026-04-28; covered registrants have an expedited path under 21 CFR Part 1301. (2) Plant marijuana broadly remains a Schedule I controlled substance under the CSA pending the DEA-1362 rulemaking, which is back before the DEA Office of Administrative Law Judges under EO 14370 with a merits hearing beginning 2026-06-29. The 2018 Farm Bill continues to govern hemp (below 0.3% THC) under USDA oversight. IRS Section 280E still denies standard business deductions for cannabis activities outside the new Schedule III bucket, and the SAFE Banking Act has not advanced in the current Congress. FinCEN requires banks to file Suspicious Activity Reports for cannabis-related transactions, and USPS prohibits mailing cannabis products. This is a synthetic overlay entity representing federal policy that applies across all US jurisdictions; see the rescheduling banner below for live docket movement.
Ask the Expert about United States — FederalControlled Substances Act, 21 U.S.C. § 801 et seq.; AG Order (final rule effective 2026-04-28); 21 CFR Part 1301; EO 14370 (DEA-1362 OALJ hearing 2026-06-29)
Drug Enforcement Administration (DEA) / Food and Drug Administration (FDA) / Office of the Attorney General